Neuroendocrine Tumors Treatment Market Size, Share & Trends Analysis Report By Treatment Type (Surgical Treatment, Pharmacological Treatment, Others), By End-User (Hospitals, Clinics, Others) and By Region (North America, Europe, APAC, Middle East and Africa, LATAM) Forecasts, 2026-2034

Neuroendocrine Tumors Treatment Market Size

The global neuroendocrine tumors treatment market size was valued at USD 3.95 billion in 2025 and is projected to grow from USD 4.36 billion in 2026 to USD 9.62 billion by 2034, registering a CAGR of 10.4% during the forecast period from 2026 to 2034. North America dominated the neuroendocrine tumors treatment market with a market share of 39.2% in 2025.

Treatment for neuroendocrine tumors involves various approaches, including surgical removal of localized tumors, medical therapies like somatostatin analogs and targeted drugs, peptide receptor radionuclide therapy (PRRT), liver-directed treatments, and radiation therapy. The specific treatment plan depends on the tumor's type, location, grade, and stage, as well as patient health. Additionally, ongoing clinical trials and research are continuously exploring new therapeutic options to improve outcomes, making personalized medicine an essential aspect of managing NETs.

The neuroendocrine tumor treatment market is expanding due to rising awareness and improved diagnostic capabilities, leading to more accurate and timely diagnoses. Additionally, advancements in treatment options, including targeted therapies and peptide receptor radionuclide therapy (PRRT), are enhancing patient outcomes and driving market growth.

Treatment Type Insights

The pharmacological treatment segment for neuroendocrine tumors treatment market is dominant. The segment is further subdivided into somatostatin analogues, targeted cancer drugs, and chemotherapy. Among these somatostatin analogues are dominant in treatment of neuroendocrine tumor. According to a study published in the Journal of Oncology, somatostatin analogs (SSAs) are one of the most preferred treatment methods for neuroendocrine tumors. SSAs are considered safe for use, which contributes to their high adoption rate. They offer a safe treatment procedure for patients, as indicated by a study published in the Journal of Patient-Reported Outcomes, where patients reported high satisfaction with long-acting injectable SSA therapy.

Many somatostatin analogues are currently under clinical trial phase and awaiting approval, indicating a growing interest and investment in this treatment modality. For example, Amyrt Pharma plc reported successful bioavailability study results for Mycapssa (octreotide capsules) in the treatment of carcinoid symptoms associated with Neuroendocrine Tumors (NET). This demonstrates the increasing research and development efforts in SSA therapy for neuroendocrine tumors.

Request Customizationto receive a tailored report.

End-User Insights

The hospital segment dominates the global neuroendocrine tumors treatment market Hospitals are often equipped with specialized oncology departments staffed by experienced healthcare professionals who can accurately diagnose and effectively treat neuroendocrine tumors such as a multidisciplinary team approach, involving oncologists, surgeons, radiologists, and pathologists, which is critical for providing comprehensive care to patients with neuroendocrine tumors. Additionally, hospitals typically have access to advanced treatment facilities, including surgical suites, imaging technologies, and radiation therapy equipment, which are essential for managing these complex tumors.

Hospitals are also often involved in clinical research and trials for new treatments and therapies for neuroendocrine tumors. This involvement in research not only benefits patients by providing access to cutting-edge treatments but also contributes to the advancement of medical knowledge and the development of new treatment options.

Overall, the hospital segment's dominance in the neuroendocrine tumors treatment market can be attributed to its ability to provide comprehensive care, access to advanced treatment facilities, multidisciplinary expertise, and involvement in research and clinical trials.

Speak to an Analystto discuss market opportunities.

Regional Insights

North America is the most significant global neuroendocrine tumors treatment market shareholder and is expected to expand substantially during the forecast period due to growing need for advanced technology in neuroendocrine tumor treatment, coupled with increasing investments in the healthcare sector. This trend is expected to propel market growth in the region.

The United States neuroendocrine tumors treatment market is leading in terms of market share. According to the American Society of Clinical Oncology, more than 12,000 people in the U.S. are diagnosed with a neuroendocrine tumor each year, with approximately 175,000 people living with the diagnosis. This rise in cases fuels market growth. Further, the approval of new neuroendocrine tumor treatment drugs by the FDA, such as belzutifan (Welireg), is a significant driver for market growth. The rise in approvals of such drugs, along with supportive insurance policies like Medicare, Medicaid, and Tricare, contributes to the overall growth of the neuroendocrine tumors treatment market.

Canada is expected to become a key player in the global neuroendocrine tumors treatment market. Collaboration between healthcare providers, research institutions, and pharmaceutical companies in Canada enhances the development and adoption of new neuroendocrine tumor treatments.

• For instance, Princess Margaret cancer centre, a Toronto-based cancer research institute collaborates with pharmaceutical companies and other research institutions to conduct clinical trials and research on neuroendocrine tumors. These collaborations help in developing and testing new treatments for patients.

Unlock Regional Insightsto access country-level data, & regional trends.

Europe Neuroendocrine Tumors Treatment Market Trends

Europe region is expected to emerge in neuroendocrine tumors treatment market. Europe hosts numerous clinical trials for NETs, offering patients access to cutting-edge treatments and contributing to the expansion of knowledge about the disease. Further, several European governments provide funding and support for research and treatment of rare diseases, including NETs, which helps drive advancements in care.

• U.K. neuroendocrine tumors treatment market is leading in terms of market share in the Europe neuroendocrine tumors treatment market due to presece of key manufacturers in this sector including AstraZeneca and GlaxoSmithKline. AstraZeneca showcased the potential of TAGRISSO (osimertinib) and IMFINZI (durvalumab) in early lung cancer settings. GlaxoSmithKline (GSK) received FDA accelerated approval for JEMPERLI (dostarlimab-gxly) for adult patients with mismatch repair-deficient (dMMR) recurrent or advanced solid tumors. GlaxoSmithKline (GSK) announced that the U.S. Food and Drug Administration (FDA) has granted accelerated approval for a new combination regimen using Tykerb (lapatinib) as a first-line, all-oral treatment for women with metastatic breast cancer. Such innovations are solidifing U.K.'s position in the market.
• Germany is expected to emerge in neuroendocrine tumors treatment market. The country’s emergence in the neuroendocrine tumors (NETs) treatment market is supported by a study in the Journal of Cancer Research and Clinical Oncology, indicating a higher susceptibility to gastrointestinal NETs in Germany, with more large intestine NETs and fewer stomach NETs compared to other European countries. These insights are expected to drive tailored neuroendocrine tumors treatment approaches and improve outcomes, contributing to market growth in Germany.

List of Key and Emerging Players in Neuroendocrine Tumors Treatment Market